195 related articles for article (PubMed ID: 30445988)
1. Effect of a high-protein diet with β-cryptoxanthin supplementation on metabolic risk factors, oxidative and inflammatory biomarkers in non-alcoholic fatty liver disease (NAFLD): study protocol for a randomized controlled clinical trial.
Haidari F; Hojhabrimanesh A; Helli B; Seyedian SS; Ahmadi-Angali K
Trials; 2018 Nov; 19(1):634. PubMed ID: 30445988
[TBL] [Abstract][Full Text] [Related]
2. An energy-restricted high-protein diet supplemented with β-cryptoxanthin alleviated oxidative stress and inflammation in nonalcoholic fatty liver disease: a randomized controlled trial.
Haidari F; Hojhabrimanesh A; Helli B; Seyedian SS; Ahmadi-Angali K
Nutr Res; 2020 Jan; 73():15-26. PubMed ID: 31841744
[TBL] [Abstract][Full Text] [Related]
3. The effects of green cardamom on blood glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1, and irisin in patients with nonalcoholic fatty liver disease and obesity: study protocol for a randomized controlled trial.
Daneshi-Maskooni M; Keshavarz SA; Mansouri S; Qorbani M; Alavian SM; Badri-Fariman M; Jazayeri-Tehrani SA; Sotoudeh G
Trials; 2017 Jun; 18(1):260. PubMed ID: 28592311
[TBL] [Abstract][Full Text] [Related]
4. Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial.
Naeini F; Namkhah Z; Tutunchi H; Rezayat SM; Mansouri S; Jazayeri-Tehrani SA; Yaseri M; Hosseinzadeh-Attar MJ
Trials; 2021 Nov; 22(1):801. PubMed ID: 34774104
[TBL] [Abstract][Full Text] [Related]
5. The effects of DASH diet on weight loss and metabolic status in adults with non-alcoholic fatty liver disease: a randomized clinical trial.
Razavi Zade M; Telkabadi MH; Bahmani F; Salehi B; Farshbaf S; Asemi Z
Liver Int; 2016 Apr; 36(4):563-71. PubMed ID: 26503843
[TBL] [Abstract][Full Text] [Related]
6. Effects of vitamin D supplementation on liver fibrogenic factors in non-alcoholic fatty liver patients with steatohepatitis: study protocol for a randomized clinical trial.
Ebrahimpour-Koujan S; Sohrabpour AA; Foroughi F; Alvandi E; Esmaillzadeh A
Trials; 2019 Mar; 20(1):153. PubMed ID: 30832722
[TBL] [Abstract][Full Text] [Related]
7. Glucose homeostasis, insulin resistance and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: Beneficial effects of supplementation with microalgae Chlorella vulgaris: A double-blind placebo-controlled randomized clinical trial.
Ebrahimi-Mameghani M; Sadeghi Z; Abbasalizad Farhangi M; Vaghef-Mehrabany E; Aliashrafi S
Clin Nutr; 2017 Aug; 36(4):1001-1006. PubMed ID: 27475283
[TBL] [Abstract][Full Text] [Related]
8. A hypocaloric high-protein diet supplemented with β-cryptoxanthin improves non-alcoholic fatty liver disease: a randomized controlled trial.
Haidari F; Hojhabrimanesh A; Helli B; Seyedian SS; Ahmadi-Angali K; Abiri B
BMC Gastroenterol; 2020 Oct; 20(1):349. PubMed ID: 33081717
[TBL] [Abstract][Full Text] [Related]
9. Effects of lutein supplementation on inflammatory biomarkers and metabolic risk factors in adults with central obesity: study protocol for a randomised controlled study.
Zhou J; Zhao D; Wang N; Zeng Z; Wang C; Hao L; Peng X
Trials; 2020 Jan; 21(1):32. PubMed ID: 31907080
[TBL] [Abstract][Full Text] [Related]
10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
11. Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial.
Daneshi-Maskooni M; Keshavarz SA; Qorbani M; Mansouri S; Alavian SM; Badri-Fariman M; Jazayeri-Tehrani SA; Sotoudeh G
BMC Complement Altern Med; 2019 Mar; 19(1):59. PubMed ID: 30871514
[TBL] [Abstract][Full Text] [Related]
12. Effect of fish oil supplementation on the concentration of miRNA-122, FGF-21 and liver fibrosis in patients with NAFLD: Study protocol for a randomized, double-blind and placebo-controlled clinical trial.
Barroso LN; Salarini J; Leite NC; Villela-Nogueira CA; Dávalos A; Carmo MDGT; Ferreira Peres WA
Clin Nutr ESPEN; 2023 Oct; 57():117-125. PubMed ID: 37739645
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the effect of curcumin and zinc co-supplementation on glycemic measurements, lipid profiles, and inflammatory and antioxidant biomarkers in overweight or obese prediabetic patients: a study protocol for a randomized double-blind placebo-controlled phase 2 clinical trial.
Karandish M; Mozaffari-Khosravi H; Mohammadi SM; Azhdari M; Cheraghian B
Trials; 2020 Nov; 21(1):991. PubMed ID: 33256795
[TBL] [Abstract][Full Text] [Related]
14. Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: Randomized, controlled, double-blind trial.
Lorvand Amiri H; Agah S; Tolouei Azar J; Hosseini S; Shidfar F; Mousavi SN
Clin Nutr; 2017 Dec; 36(6):1490-1497. PubMed ID: 27720403
[TBL] [Abstract][Full Text] [Related]
15. Propolis supplementation in obese patients with non-alcoholic fatty liver disease: effects on glucose homeostasis, lipid profile, liver function, anthropometric indices and meta-inflammation.
Nikbaf-Shandiz M; Tutunchi H; Khoshbaten M; Nazari Bonab H; Ebrahimi-Mameghani M
Food Funct; 2022 Nov; 13(22):11568-11578. PubMed ID: 36263703
[TBL] [Abstract][Full Text] [Related]
16. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.
Barchetta I; Del Ben M; Angelico F; Di Martino M; Fraioli A; La Torre G; Saulle R; Perri L; Morini S; Tiberti C; Bertoccini L; Cimini FA; Panimolle F; Catalano C; Baroni MG; Cavallo MG
BMC Med; 2016 Jun; 14():92. PubMed ID: 27353492
[TBL] [Abstract][Full Text] [Related]
17. Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol.
Lambert JE; Parnell JA; Eksteen B; Raman M; Bomhof MR; Rioux KP; Madsen KL; Reimer RA
BMC Gastroenterol; 2015 Dec; 15():169. PubMed ID: 26635079
[TBL] [Abstract][Full Text] [Related]
18. Effect of green coffee extract supplementation on serum adiponectin concentration and lipid profile in patients with non-alcoholic fatty liver disease: A randomized, controlled trial.
Hosseinabadi S; Rafraf M; Asghari S; Asghari-Jafarabadi M; Vojouhi S
Complement Ther Med; 2020 Mar; 49():102290. PubMed ID: 32147076
[TBL] [Abstract][Full Text] [Related]
19. Oleoylethanolamide supplementation in obese patients newly diagnosed with non-alcoholic fatty liver disease: Effects on metabolic parameters, anthropometric indices, and expression of PPAR-α, UCP1, and UCP2 genes.
Tutunchi H; Ostadrahimi A; Saghafi-Asl M; Hosseinzadeh-Attar MJ; Shakeri A; Asghari-Jafarabadi M; Roshanravan N; Farrin N; Naemi M; Hasankhani M
Pharmacol Res; 2020 Jun; 156():104770. PubMed ID: 32217148
[TBL] [Abstract][Full Text] [Related]
20. Modified high-intensity interval training reduces liver fat and improves cardiac function in non-alcoholic fatty liver disease: a randomized controlled trial.
Hallsworth K; Thoma C; Hollingsworth KG; Cassidy S; Anstee QM; Day CP; Trenell MI
Clin Sci (Lond); 2015 Dec; 129(12):1097-105. PubMed ID: 26265792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
